Drug Reference for FDA Approved Epilepsy Drugs @ Neurotransmitter.net
Generic Name: IUPAC Name: Database Search Links: |
Initial Approval: Product Insert: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: |
Possible Mechanisms of Action: Acetazolamide inhibits carbonic anhydrase isozymes CA II (1), CA III (2), CA IV (3), CA VA (4), CA VB (5), CA VI (6), CA VII (7), CA IX (1), CA XII (8), CA XIII (9), and CA XIV (10). |
Chemical Class: PubChem 2D Structure: |
Generic Name: Common Chemical Name: Dosage Forms/Routes: Database Search Links: |
Initial Approval: Product Insert: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. Generalized tonic-clonic seizures (grand mal). Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine. Trigeminal Neuralgia: Carbamazepine is indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. |
Possible Mechanisms of Action: Carbamazepine inhibits voltage-gated sodium channels in a use- dependent manner (11). The drug is an antagonist at adenosine A1 receptors (12, 13, 14). Carbamazepine may be an agonist at adenosine A2A and/or A2B receptors (14). Carbamazepine also inhibits adenylyl cyclase via an unidentified mechanism (15). In addition, carbamazepine may be a histone deacetylase inhibitor (63). |
Chemical Class: PubChem 2D Structure: |
Generic Name: IUPAC Name: Dosage Forms/Routes: Database Search Links: |
Initial Approval: Product Insert: RxList: Epocrates: Empirical Formula: C15H10ClN3O3 Molecular Mass: |
Indications: |
Possible Mechanism of Action: |
Chemical Class: |
Generic Name: Trade Name: Major Metabolites: Dosage Forms/Routes: Database Search Links: |
Initial Approval: Product Insert: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: |
Possible Mechanism of Action: Clorazepate is a nonselective benzodiazepine agonist (17). |
Chemical Class: |
Generic Name: Trade Name: Major Metabolites: Dosage Forms/Routes: Database Search Links: |
Initial Approval: Product Insert: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: Diazepam is useful premedication for relief of anxiety and tension in patients who are to undergo surgical procedures. Diazepam injection is a useful adjunct in status epilepticus and severe recurrent convulsive seizures. |
Possible Mechanisms of Action: Diazepam is a nonselective benzodiazepine agonist (18). Diazepam is also an agonist at peripheral benzodiazepine receptors (19). |
Chemical Class: |
Generic Name: Major Metabolites: Dosage Forms/Routes: Database Search Links: |
Initial Approval: Product Insert: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: All dosage forms: Monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures; sole or adjunctive therapy in the treatment of simple and complex absence seizures; adjunct for the treatment of patients with multiple seizure types that include absence seizures |
Possible Mechanisms of Action: |
Chemical Class: |
Generic Name: IUPAC Name: Dosage Forms/Routes: Database Search Links: |
Initial Approval: Product Insert: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: |
Possible Mechanisms of Action: Ethosuximide is a T-type calcium channel blocker (26, 30). The drug may also reduce noninactivating Na+ currents and Ca2+- activated K+ currents in thalamic and cortical neurons (31, 32). |
Chemical Class: PubChem 2D Structure: |
Generic Name: IUPAC Name: Dosage Forms/Routes: Database Search Links: |
Initial Approval: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: Felbamate is recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. If these criteria are met and the patient has been fully advised of the risk and has provided written, informed consent, felbamate can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children. |
Possible Mechanisms of Action: |
Chemical Class: PubChem 2D Structure: |
Generic Name: IUPAC Name: Dosage Forms/Routes: Database Search Links: |
Initial Approval: Product Insert: RxList: Epocrates: Molecular Mass: |
Indications: |
Possible Mechanisms of Action: Fosphenytoin is a prodrug for phenytoin. Phenytoin inhibits voltage-gated sodium channels in a use- dependent manner (11). Phenytoin is also a low affinity inhibitor at T-type calcium channels that contain the alpha1H subunit (29). In addition, phenytoin inhibits the persistent Na+ current (INaP) (47). |
Chemical Class: |
Generic Name: IUPAC Name: Dosage Forms/Routes: Database Search Links: |
Initial Approval: Product Insert: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: Gabapentin is also indicated for the management of postherpetic neuralgia in adults. |
Possible Mechanisms of Action: |
Chemical Class: PubChem 2D Structure: |
Generic Name: Major Metabolite: Dosage Forms/Routes: Database Search Links: |
Initial Approval: Product Insert: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: |
Possible Mechanisms of Action: |
Chemical Class: |
Generic Name: IUPAC Name: Dosage Forms/Routes: Database Search Links: |
Initial Approval: Product Insert: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: |
Possible Mechanisms of Action: |
Chemical Class: PubChem 2D Structure: |
Generic Name: IUPAC Name: Dosage Forms/Routes: Major Metabolite: Database Search Links: |
Initial Approval: Prescribing Information: RxList: Molecular Mass: |
Indications: Lorazepam injection is also indicated in adult patients for preanesthetic medication, producing sedation (sleepiness or drowsiness), relief of anxiety, and a decreased ability to recall events related to the day of surgery. It is most useful in those patients who are anxious about their surgical procedure and who would prefer to have diminished recall of the events of the day of surgery. |
Possible Mechanism of Action: Lorazepam is a nonselective benzodiazepine agonist (66). |
Chemical Class: PubChem 2D Structure: |
Generic Name: Common Chemical Name: Dosage Forms/Routes: Database Search Links: |
Initial Approval: Product Insert: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: |
Possible Mechanisms of Action: Oxcarbazepine inhibits voltage-gated sodium channels in a use- dependent manner (44). The drug is also a weak inhibitor of L-type calcium channels (45). |
Chemical Class: PubChem 2D Structure: |
Generic Name: Database Search Links: |
Manufacturers: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: Phenobarbital is also indicated for the short-term treatment of insomnia and for use as a preanesthetic and sedative. |
Possible Mechanisms of Action: Phenobarbital positively modulates the flow of chloride ions through GABA-A receptor complexes by interacting with the barbiturate binding site (46). |
Chemical Class: PubChem 2D Structure: |
Generic Name: IUPAC Name: Dosage Forms/Routes: Database Search Links: |
Initial Approval: Product Insert: [Link ] (Infatabs) RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: Chewable tablets: control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery
|
Possible Mechanisms of Action: Phenytoin inhibits voltage-gated sodium channels in a use- dependent manner (11). Phenytoin is also a low affinity inhibitor at T-type calcium channels that contain the alpha1H subunit (29). In addition, phenytoin inhibits the persistent Na+ current (INaP) (47). |
Chemical Class: PubChem 2D Structure: |
Generic Name: IUPAC Name: Dosage Forms/Routes: Database Search Links: |
Initial Approval: Product Insert: Epocrates: Empirical Formula: Molecular Mass: |
Indications: |
Possible Mechanisms of Action: Phenytoin inhibits voltage-gated sodium channels in a use- dependent manner (11). Phenytoin is also a low affinity inhibitor at T-type calcium channels that contain the alpha1H subunit (29). In addition, phenytoin inhibits the persistent Na+ current (INaP) (47). |
Chemical Class: PubChem 2D Structure: |
Generic Name: IUPAC Name: Dosage Forms/Routes: Database Search Links: |
Initial Approval: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: |
Possible Mechanisms of Action: Pregabalin binds to the alpha(2)delta-1 and alpha(2)delta-2 regulatory subunits of voltage-gated calcium channels (48). Pregabalin binds with higher affinity to the alpha(2)delta-2 subunit (48). |
Chemical Class: PubChem 2D Structure: |
Generic Name: IUPAC Name: Dosage Forms/Routes: Database Search Links: |
Initial Approval: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: |
Possible Mechanisms of Action: |
Chemical Class: |
Generic Name: IUPAC Name: Dosage Forms/Routes: Database Search Links: |
Initial Approval: Product Insert: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: |
Possible Mechanisms of Action: Tiagabine inhibits the GABA reuptake transporter (49). |
Chemical Class: PubChem 2D Structure: |
Generic Name: Common Chemical Name: Dosage Forms/Routes: Database Search Links: |
Initial Approval: Product Insert: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: |
Possible Mechanisms of Action: Topiramate inhibits carbonic anhydrase isozymes such as CA II (50), CA IV (50, 51), and CA V (52). Topiramate has also been shown to inhibit both the fast and persistent components of sodium currents in neocortical cells (53). In addition, the drug may inhibit L-type calcium channels (54, 55). Topiramate also inhibits inward currents at some subtypes of kainate and AMPA glutamate receptors (56, 57). Finally, the drug may act as a histone deacetylase inhibitor (64). |
Chemical Class: PubChem 2D Structure: |
Generic Name: IUPAC Name: Dosage Forms/Routes: Database Search Links: |
Initial Approval: Empirical Formula: Molecular Mass: |
Indications: |
Possible Mechanisms of Action: Trimethadione and its active metabolite, dimethadione, are T-type calcium channel inhibitors (58). |
Chemical Class: |
Generic Name: Major Metabolites: Dosage Forms/Routes: Database Search Links: |
Initial Approval: Product Insert: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: |
Possible Mechanisms of Action: |
Chemical Class: |
Generic Name: IUPAC Name: Dosage Forms/Routes: Database Search Links: |
Initial Approval: Product Insert: RxList: Epocrates: Empirical Formula: Molecular Mass: |
Indications: |
Possible Mechanisms of Action: |
Chemical Class: PubChem 2D Structure: |
References:
1. . Winum JY, Cecchi A, Montero JL, Innocenti A, Scozzafava A, Supuran CT.
Carbonic anhydrase inhibitors. Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with boron-containing sulfonamides, sulfamides, and sulfamates: toward agents for boron neutron capture therapy of hypoxic tumors.
Bioorg Med Chem Lett. 2005 Jul 1;15(13):3302-6.Bioorg Med Chem Lett. 2005 Jul 1;15(13):3302-6. [Abstract]
2. Lehtonen J, Shen B, Vihinen M, Casini A, Scozzafava A, Supuran CT, Parkkila AK, Saarnio J, Kivela AJ, Waheed A, Sly WS, Parkkila S.
Characterization of CA XIII, a novel member of the carbonic anhydrase isozyme family.
J Biol Chem. 2004 Jan 23;279(4):2719-27. [Full Text]
3. Innocenti A, Firnges MA, Antel J, Wurl M, Scozzafava A, Supuran CT.
Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides.
Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54. [Abstract]
4. Vullo D, Franchi M, Gallori E, Antel J, Scozzafava A, Supuran CT.
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
J Med Chem. 2004 Feb 26;47(5):1272-9. [Abstract]
5. Fujikawa-Adachi K, Nishimori I, Taguchi T, Onishi S.
Human mitochondrial carbonic anhydrase VB. cDNA cloning, mRNA expression, subcellular localization, and mapping to chromosome x.
J Biol Chem. 1999 Jul 23;274(30):21228-33. [Full Text]
6. Murakami H, Sly WS.
Purification and characterization of human salivary carbonic anhydrase.
J Biol Chem. 1987 Jan 25;262(3):1382-8. [Full Text]
7. Vullo D, Voipio J, Innocenti A, Rivera C, Ranki H, Scozzafava A, Kaila K, Supuran CT.
Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides.
Bioorg Med Chem Lett. 2005 Feb 15;15(4):971-6. [Abstract]
8. Vullo D, Innocenti A, Nishimori I, Pastorek J, Scozzafava A, Pastorekova S, Supuran CT.
Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?
Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9. [Abstract]
9. Lehtonen J, Shen B, Vihinen M, Casini A, Scozzafava A, Supuran CT, Parkkila AK, Saarnio J, Kivela AJ, Waheed A, Sly WS, Parkkila S.
Characterization of CA XIII, a novel member of the carbonic anhydrase isozyme family.
J Biol Chem. 2004 Jan 23;279(4):2719-27. [Full Text]
10. Fujikawa-Adachi K, Nishimori I, Taguchi T, Onishi S.
Human carbonic anhydrase XIV (CA14): cDNA cloning, mRNA expression, and mapping to chromosome 1.
Genomics. 1999 Oct 1;61(1):74-81. [Abstract]
11. Kuo CC, Chen RS, Lu L, Chen RC.
Carbamazepine inhibition of neuronal Na+ currents: quantitative distinction from phenytoin and possible therapeutic implications.
Mol Pharmacol. 1997 Jun;51(6):1077-83. [Full Text]
12. Van Calker D, Steber R, Klotz KN, Greil W.
Carbamazepine distinguishes between adenosine receptors that mediate different second messenger responses.
Eur J Pharmacol. 1991 Apr 25;206(4):285-90. [Abstract]
13. Biber K, Walden J, Gebicke-Harter P, Berger M, van Calker D.
Carbamazepine inhibits the potentiation by adenosine analogues of agonist induced inositolphosphate formation in hippocampal astrocyte cultures.
Biol Psychiatry. 1996 Oct 1;40(7):563-7. [Abstract]
14. Okada M, Kiryu K, Kawata Y, Mizuno K, Wada K, Tasaki H, Kaneko S.
Determination of the effects of caffeine and carbamazepine on striatal dopamine release by in vivo microdialysis.
Eur J Pharmacol. 1997 Feb 26;321(2):181-8. [Abstract]
15. Chen G, Pan B, Hawver DB, Wright CB, Potter WZ, Manji HK.
Attenuation of cyclic AMP production by carbamazepine.
J Neurochem. 1996 Nov;67(5):2079-86. [Abstract]
16. Mihic SJ, Whiting PJ, Klein RL, Wafford KA, Harris RA.
A single amino acid of the human gamma-aminobutyric acid type A receptor gamma 2 subunit determines benzodiazepine efficacy.
J Biol Chem. 1994 Dec 30;269(52):32768-73. [Full Text]
17. Griebel G, Sanger DJ, Perrault G.
Further evidence for differences between non-selective and BZ-1 (omega 1) selective, benzodiazepine receptor ligands in murine models of "state" and "trait" anxiety.
Neuropharmacology. 1996;35(8):1081-91. [Abstract]
18. Mihic SJ, Whiting PJ, Klein RL, Wafford KA, Harris RA.
A single amino acid of the human gamma-aminobutyric acid type A receptor gamma 2 subunit determines benzodiazepine efficacy.
J Biol Chem. 1994 Dec 30;269(52):32768-73. [Full Text]
19. Marino F, Cattaneo S, Cosentino M, Rasini E, Di Grazia L, Fietta AM, Lecchini S, Frigo G.
Diazepam stimulates migration and phagocytosis of human neutrophils: possible contribution of peripheral-type benzodiazepine receptors and intracellular calcium.
Pharmacology. 2001 Jul;63(1):42-9. [Abstract]
20. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS.
Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen
J Biol Chem. 2001 Sep 28;276(39):36734-41. [Full Text]
21. Ueda Y, Willmore LJ.
Molecular regulation of glutamate and GABA transporter proteins by valproic acid in rat hippocampus during epileptogenesis.
Exp Brain Res 2000 Aug;133(3):334-9 [Abstract]
22. Johannessen CU.
Mechanisms of action of valproate: a commentatory.
Neurochem Int. 2000 Aug-Sep;37(2-3):103-10. [Abstract]
23. Vreugdenhil M, Wadman WJ.
Modulation of sodium currents in rat CA1 neurons by carbamazepine and valproate after kindling epileptogenesis.
Epilepsia 1999 Nov;40(11):1512-22 [Abstract]
24. Loscher W.
Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.
CNS Drugs 2002;16(10):669-94 [Abstract]
25. Cutrer FM.
Antiepileptic drugs: how they work in headache.
Headache. 2001 Nov-Dec;41 Suppl 1:S3-10. [Abstract]
26. Gomora JC, Daud AN, Weiergraber M, Perez-Reyes E.
Block of cloned human T-type calcium channels by succinimide antiepileptic drugs.
Mol Pharmacol 2001 Nov;60(5):1121-32 [Full Text]
27. Kuo CC, Lin BJ, Chang HR, Hsieh CP.
Use-dependent inhibition of the N-methyl-D-aspartate currents by felbamate: a gating modifier with selective binding to the desensitized channels.
Mol Pharmacol. 2004 Feb;65(2):370-80. [Full Text]
28. Kleckner NW, Glazewski JC, Chen CC, Moscrip TD.
Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate: insights into the mechanism of action.
J Pharmacol Exp Ther. 1999 May;289(2):886-94. [Full Text]
29. Todorovic SM, Perez-Reyes E, Lingle CJ.
Anticonvulsants but not general anesthetics have differential blocking effects on different T-type current variants.
Mol Pharmacol. 2000 Jul;58(1):98-108. [Full Text]
30. Huguenard JR.
Block of T -Type Ca(2+) Channels Is an Important Action of Succinimide Antiabsence Drugs.
Epilepsy Curr. 2002 Mar;2(2):49-52. [Full Text]
31. Leresche N, Parri HR, Erdemli G, Guyon A, Turner JP, Williams SR, Asprodini E, Crunelli V.
On the action of the anti-absence drug ethosuximide in the rat and cat thalamus.
J Neurosci. 1998 Jul 1;18(13):4842-53. [Full Text]
32. Crunelli V, Leresche N.
Block of Thalamic T-Type Ca(2+) Channels by Ethosuximide Is Not the Whole Story.
Epilepsy Curr. 2002 Mar;2(2):53-56. [Full Text]
33. Marais E, Klugbauer N, Hofmann F.
Calcium channel alpha(2)delta subunits-structure and Gabapentin binding.
Mol Pharmacol 2001 May;59(5):1243-8 [Full Text]
34. Qin N, Yagel S, Momplaisir ML, Codd EE, D'Andrea MR.
Molecular cloning and characterization of the human voltage-gated calcium channel alpha(2)delta-4 subunit.
Mol Pharmacol 2002 Sep;62(3):485-96 [Full Text]
35. Ng GY, Bertrand S, Sullivan R, Ethier N, Wang J, Yergey J, Belley M, Trimble L, Bateman K, Alder L, Smith A, McKernan R, Metters K, O'Neill GP, Lacaille JC, Hebert TE.
Gamma-aminobutyric acid type B receptors with specific heterodimer composition and postsynaptic actions in hippocampal neurons are targets of anticonvulsant gabapentin action.
Mol Pharmacol. 2001 Jan;59(1):144-52. [Full Text]
36. Bertrand S, Ng GY, Purisai MG, Wolfe SE, Severidt MW, Nouel D, Robitaille R, Low MJ, O'Neill GP, Metters K, Lacaille JC, Chronwall BM, Morris SJ.
The anticonvulsant, antihyperalgesic agent gabapentin is an agonist at brain gamma-aminobutyric acid type B receptors negatively coupled to voltage-dependent calcium channels.
J Pharmacol Exp Ther. 2001 Jul;298(1):15-24. [Full Text]
37. Suarez LM, Suarez F, Del Olmo N, Ruiz M, Gonzalez-Escalada JR, Solis JM.
Presynaptic NMDA autoreceptors facilitate axon excitability: a new molecular target for the anticonvulsant gabapentin.
Eur J Neurosci. 2005 Jan;21(1):197-209. [Abstract]
38. Cronin NB, O'Reilly A, Duclohier H, Wallace BA.
Binding of the anticonvulsant drug lamotrigine and the neurotoxin batrachotoxin to voltage-gated sodium channels induces conformational changes associated with block and steady-state activation.
J Biol Chem 2003 Mar 21;278(12):10675-82 [Full Text]
39. Catterall WA.
Molecular properties of brain sodium channels: an important target for anticonvulsant drugs.
Adv Neurol 1999;79:441-56 [Abstract]
40. Stefani A, Spadoni F, Siniscalchi A, Bernardi G.
Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications.
Eur J Pharmacol. 1996 Jun 20;307(1):113-6. [Abstract]
41. Wang SJ, Huang CC, Hsu KS, Tsai JJ, Gean PW.
Inhibition of N-type calcium currents by lamotrigine in rat amygdalar neurones.
Neuroreport. 1996 Nov 25;7(18):3037-40. [Abstract]
42. Lukyanetz EA, Shkryl VM, Kostyuk PG.
Selective blockade of N-type calcium channels by levetiracetam.
Epilepsia. 2002 Jan;43(1):9-18. [Abstract]
43. Rho JM, Donevan SD, Rogawski MA.
Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate.
J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [Full Text]
44. McLean MJ, Schmutz M, Wamil AW, Olpe HR, Portet C, Feldmann KF.
Oxcarbazepine: mechanisms of action.
Epilepsia. 1994;35 Suppl 3:S5-9.Epilepsia. 1994;35 Suppl 3:S5-9. [Abstract]
45. Schmutz M, Brugger F, Gentsch C, McLean MJ, Olpe HR.
Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action.
Epilepsia. 1994;35 Suppl 5:S47-50. [Abstract]
46. Allan AM, Harris RA.
Anesthetic and convulsant barbiturates alter gamma-aminobutyric acid-stimulated chloride flux across brain membranes.
J Pharmacol Exp Ther. 1986 Sep;238(3):763-8. [Abstract]
47. Lampl I, Schwindt P, Crill W.
Reduction of cortical pyramidal neuron excitability by the action of phenytoin on persistent Na+ current.
J Pharmacol Exp Ther. 1998 Jan;284(1):228-37. [Full Text]
48. Gong HC, Hang J, Kohler W, Li L, Su TZ.
Tissue-specific expression and gabapentin-binding properties of calcium channel alpha2delta subunit subtypes.
J Membr Biol. 2001 Nov 1;184(1):35-43. [Abstract]
49. Suzdak PD, Foged C, Andersen KE.
Quantitative autoradiographic characterization of the binding of [3H]tiagabine (NNC 05-328) to the GABA uptake carrier.
Brain Res. 1994 Jun 6;647(2):231-41. [Abstract]
50. Dodgson SJ, Shank RP, Maryanoff BE.
Topiramate as an inhibitor of carbonic anhydrase isoenzymes.
Epilepsia 2000;41 Suppl 1:S35-9 [Abstract]
51. Masereel B, Rolin S, Abbate F, Scozzafava A, Supuran CT.
Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties.
J Med Chem. 2002 Jan 17;45(2):312-20. [Abstract]
52. De Simone G, Di Fiore A, Menchise V, Pedone C, Antel J, Casini A, Scozzafava A, Wurl M, Supuran CT.
Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies.
Bioorg Med Chem Lett. 2005 May 2;15(9):2315-20. [Abstract]
53. Taverna, S., Sancini, G., Mantegazza, M., Franceschetti, S., Avanzini, G.
Inhibition of Transient and Persistent Na+ Current Fractions by the New Anticonvulsant Topiramate
J Pharmacol Exp Ther 1999 288: 960-968 [Full Text]
54. Zhang X, Velumian AA, Jones OT, Carlen PL.
Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate.
Epilepsia. 2000;41 Suppl 1:S52-60. [Abstract]
55. Russo E, Constanti A, Ferreri G, Citraro R, De Sarro G.
Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy.
Neuropharmacology. 2004 May;46(6):865-78. [Abstract]
56. Poulsen CF, Simeone TA, Maar TE, Smith-Swintosky V, White HS, Schousboe A.
Modulation by topiramate of AMPA and kainate mediated calcium influx in cultured cerebral cortical, hippocampal and cerebellar neurons.
Neurochem Res. 2004 Jan;29(1):275-82.Neurochem Res. 2004 Jan;29(1):275-82. [Abstract]
57. Gibbs JW 3rd, Sombati S, DeLorenzo RJ, Coulter DA.
Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons.
Epilepsia. 2000;41 Suppl 1:S10-6. [Abstract]
58. Zhang YF, Gibbs JW 3rd, Coulter DA.
Anticonvulsant drug effects on spontaneous thalamocortical rhythms in vitro: ethosuximide, trimethadione, and dimethadione.
Epilepsy Res. 1996 Feb;23(1):15-36. [Abstract]
59. Sakaue A, Honda M, Tanabe M, Ono H.
Antinociceptive effects of sodium channel-blocking agents on acute pain in mice.
J Pharmacol Sci. 2004 Jun;95(2):181-8. [Full Text]
60. Suzuki S, Kawakami K, Nishimura S, Watanabe Y, Yagi K, Seino M, Miyamoto K.
Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex.
Epilepsy Res. 1992 Jun;12(1):21-7. [Abstract]
61. Kito M, Maehara M, Watanabe K.
Mechanisms of T-type calcium channel blockade by zonisamide.
Seizure. 1996 Jun;5(2):115-9. [Abstract]
62. Nishimori I, Vullo D, Innocenti A, Scozzafava A, Mastrolorenzo A, Supuran CT.
Carbonic anhydrase inhibitors: Inhibition of the transmembrane isozyme XIV with sulfonamides.
Bioorg Med Chem Lett. 2005 Jul 20 [Abstract]
63. Beutler AS, Li S, Nicol R, Walsh MJ.
Carbamazepine is an inhibitor of histone deacetylases.
Life Sci. 2005 May 13;76(26):3107-15. [Abstract]
64. Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M.
The activity of antiepileptic drugs as histone deacetylase inhibitors.
Epilepsia. 2004 Jul;45(7):737-44. [Abstract]
65. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B.
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9861-6. [Full Text]
66.
Mihic SJ, Whiting PJ, Klein RL, Wafford KA, Harris RA.
A single amino acid of the human gamma-aminobutyric acid type A receptor gamma 2 subunit determines benzodiazepine efficacy.
J Biol Chem. 1994 Dec 30;269(52):32768-73. [Full Text]